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Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery
Genomic studies have greatly advanced our understanding of the multifactorial aetiology of type 2 diabetes mellitus
(T2DM) as well as the multiple subtypes of monogenic diabetes mellitus. In this Review, we discuss the existing
pharmacogenetic evidence in both monogenic diabetes mellitus and T2DM. We highlight mechanistic insights from the
study of adverse effects and the efficacy of antidiabetic drugs. The identification of extreme sulfonylurea sensitivity in
patients with diabetes mellitus owing to heterozygous mutations in HNF1A represents a clear example of how
pharmacogenetics can direct patient care. However, pharmacogenomic studies of response to antidiabetic drugs in T2DM
has yet to be translated into clinical practice, although some moderate genetic effects have now been described that merit
follow-up in trials in which patients are selected according to genotype. We also discuss how future pharmacogenomic
findings could provide insights into treatment response in diabetes mellitus that, in addition to other areas of human
genetics, facilitates drug discovery and drug development for T2DM.
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